By Hyunjin Choi
JLK Inspection, an AI-enhanced medical solution provider, announced that it will seek Initial Public Offering(IPO) to go public on KOSDAQ, submitting the registration statement to the Financial Services Commission after passing the preliminary screening review by Korean Exchange(KRX) on the 30th last month.
The market is eyeing on JLK Inspection in the process of IPO under the technology exception policy since it will be the first AI-based medical company on the KOSDAQ market. The company plans to secure approximately a maximum of KRW 29 bn (USD 25 mm) by offering 2 million stocks with the IPO price band between 11,000 won and 14,500 won per share.
The IPO price is to set up during the book-building session on Nov. 26-27. Public subscriptions will be held on Dec. 2-3, and JLK Inspection expects that the listing is finalized within this year. The lead manager is Korea Investment & Securities Co.
Founded in 2014, JLK Inspection(a Born2Global member from 2017~2019) is a medical solutions provider specializing AI-enhanced technology.
The company released AIHuB, an all-in-one medical platform to detect 37 medical conditions in 14 different body parts: strokes, Alzheimer’s, prostate cancer, lung cancer, thyroids cancer, breast cancer, and joint disease. To support a doctor’s diagnosis, AIHuB analyzes nationwide scales of MR images up to 1.5M slides from 14K people based on deep learning technology. After the analysis, it provides a real-time diagnosis support on site for practitioners.
While competitors use only CT to detect diseases, AIHuB heightens the accuracy, using CT, MRI, MRA, and mammography data all together.These solutions are approved by the Ministry of Food and Drug Safety in South Korea as an AI-based class Ⅲ computer aided diagnosis system. It has obtained CE mark for AI-based medical solutions in accordance with the European Medical Device Directive(MDD).